Jaguar Health (NASDAQ:JAGX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research report sent to investors on Monday. The firm issued a sell rating on the biotechnology company’s stock.

Jaguar Health Stock Up 14.7 %

JAGX opened at $0.18 on Monday. The company has a current ratio of 2.00, a quick ratio of 1.34 and a debt-to-equity ratio of 6.33. Jaguar Health has a 52-week low of $0.05 and a 52-week high of $1.22. The company has a 50 day moving average of $0.09 and a two-hundred day moving average of $0.18.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.